NASDAQ: FENCFennec Pharmaceuticals Inc Stock
$5.65+0.21 (+3.86%)
Updated Apr 23, 2025
FENC Price
$5.65
Fair Value Price
N/A
Market Cap
$155.91M
52 Week Low
$3.96
52 Week High
$10.07
P/E
-282.5x
P/B
-26.55x
P/S
3.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$47.54M
Earnings
-$436.00k
Gross Margin
93.3%
Operating Margin
8.41%
Profit Margin
-0.9%
Debt to Equity
-8.65
Operating Cash Flow
$27M
Beta
0.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FENC Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FENC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FENC
Ranked#32 of 461
Ranked#32 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.09 | A | |
| $23.12 | A |
Be the first to know about important FENC news, forecast changes, insider trades & much more!
FENC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FENC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FENC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FENC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
FENC's Earnings (EBIT) of $4.00M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more FENC due diligence checks available for Premium users.
Valuation
FENC fair value
Fair Value of FENC stock based on Discounted Cash Flow (DCF)
Price
$5.65
Fair Value
-$3.34
Undervalued by
269.30%
FENC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FENC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-282.5x
Industry
-284.95x
Market
26.95x
FENC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-26.55x
Industry
4.25x
FENC's financial health
Profit margin
Revenue
$7.9M
Net Income
-$2.0M
Profit Margin
-25%
FENC's Earnings (EBIT) of $4.00M... subscribe to Premium to read more.
Interest Coverage Financials
FENC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$44.9M
Liabilities
$50.8M
Debt to equity
-8.65
FENC's short-term assets ($44.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FENC's short-term assets ($44.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FENC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FENC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$0.0
Financing
-$12.2M
FENC's operating cash flow ($26.98M)... subscribe to Premium to read more.
Debt Coverage Financials
FENC vs Biotech Stocks
Fennec Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.